Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Patient Satisfaction 2Urologic Neoplasms 1Thyroid Cancer, Papillary 1Sarcoma, Ewing 1Sarcoma 1Radiation Injuries 1Patient Preference 1Patient Acceptance of Health Care 1Osteosarcoma 1Osteitis Deformans 1Neoplasms 1Breast Neoplasms 1Bone Neoplasms 1

Interventions

Cyclophosphamide 16Temozolomide 13Vincristine 10Irinotecan 8Melphalan 7Doxorubicin 7Topotecan 6Granulocyte Colony-Stimulating Factor 6Busulfan 6fludarabine 5cabozantinib 5Etoposide 5Drug Therapy 5liposomal doxorubicin 4Sirolimus 4Ifosfamide 4Filgrastim 4regorafenib 3pegfilgrastim 3irinotecan sucrosofate 3fludarabine phosphate 3Zoledronic Acid 3Radiotherapy 3Nivolumab 3Magnetic Resonance Spectroscopy 3Gemcitabine 3Cisplatin 3Bone Marrow Transplantation 3Albumin-Bound Paclitaxel 3pegylated granulocyte colony-stimulating factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Sarcoma, Ewing × delta 24-sterol reductase × Clear all
NCT01882231 2017-05-08

Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma

Vanderbilt-Ingram Cancer Center

Phase NA Terminated
6 enrolled
Sarcoma

Bone Neoplasms, Osteitis Deformans, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡